AN2 Therapeutics, Inc. announces significant progress in its key research and development projects

The company plans to officially launch Phase II clinical trials in the third quarter of 2026, marking a new stage in the development of this therapy. According to the plan, the earliest expected time point for the first batch of data readout from this study is the fourth quarter of 2026. Subsequently, throughout 2027, new clinical data will continue to be released, providing key evidence for evaluating the safety and efficacy of the therapy. The announcement of this timeline provides clear expectations for investors and market observers who are following the company's R&D progress. The subsequent data readout schedule will span the entire year of 2027, forming a continuous stream of data.